| Předmět: |
|
| Zdroj: |
Respiratory Therapeutics Week; 9/30/2024, p1730-1730, 1p |
| Abstrakt: |
A recent study conducted by researchers at the National and Kapodistrian University of Athens provides new insights into pulmonary fibrosis (PF), a severe and irreversible lung disease characterized by progressive scarring. The study highlights the dysregulation of the yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling pathway as a critical factor in PF. The researchers suggest that targeting this pathway could offer a promising therapeutic avenue for improving treatment outcomes. Potential treatments that inhibit YAP/TAZ activity and demonstrate antifibrotic effects have been identified in preclinical studies, but further research is needed to validate these approaches and translate them into clinical practice. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
